Grose W E, Lehane D E, Dixon D O, Fletcher W S, Stuckey W J
Cancer Treat Rep. 1985 Jun;69(6):577-81.
One hundred eligible patients with inoperable, locally advanced or metastatic squamous cell carcinoma of the head and neck region following prior therapy were randomized to receive im methotrexate (50 patients) or iv cisplatin (50 patients). Methotrexate produced a complete plus partial response rate of 16.0% and cisplatin produced a partial response rate of 8.0%, with median durations of response of 18 and 8 weeks, respectively. The corresponding median survival times were 20 and 18 weeks. Methotrexate responders survived 60 weeks, versus 17 weeks for nonresponders. The corresponding survival times for cisplatin-treated patients were 38 and 18 weeks. Good pretreatment performance status had a significantly positive effect on survival (P = 0.04), but prior therapy did not. Toxicity secondary to either agent occurred with the expected frequency. The two agents examined showed comparable antitumor activity in patients with squamous cell carcinoma of the head and neck who had not previously received chemotherapy.
100例先前接受过治疗的无法手术的局部晚期或转移性头颈部鳞状细胞癌合格患者被随机分为两组，分别接受甲氨蝶呤（50例）或静脉注射顺铂（50例）治疗。甲氨蝶呤的完全缓解加部分缓解率为16.0%，顺铂的部分缓解率为8.0%，缓解持续时间中位数分别为18周和8周。相应的中位生存时间分别为20周和18周。甲氨蝶呤治疗有反应者生存60周，无反应者生存17周。顺铂治疗患者的相应生存时间分别为38周和18周。良好的预处理体能状态对生存有显著的积极影响（P = 0.04），但先前治疗对生存无影响。两种药物的继发毒性发生频率符合预期。在未接受过化疗的头颈部鳞状细胞癌患者中，所研究的两种药物显示出相当的抗肿瘤活性。
